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Abstract 
Current biomaterials for auricular replacement are associated with high rates of infection and 
extrusion. The development of new auricular biomaterials that mimic the mechanical 
properties of native tissue and promote desirable cellular interactions may prevent implant 
failure. A porous 3D nanocomposite scaffold (NS) based on POSS-PCU (a polycarbonate 
soft segment and a polyhedral oligomeric silsesquioxanes nanocage) was developed with an 
elastic modulus similar to native ear. In vitro biological interactions on this NS revealed 
greater protein adsorption, increased fibroblast adhesion, proliferation and collagen 
production compared with Medpor® (the current synthetic auricular implant). In vivo the 
POSS-PCU with larger pores (NS2; 150-250μm) had greater tissue ingrowth (~5.8× and 
~1.4× fold increase) than the POSS-PCU with smaller pores (NS1; 100-50μm) and when 
compared to Medpor® (>100μm). The NS2 with the larger pores demonstrates a reduced 
fibrotic encapsulation compared with NS1 and Medpor® (~4.1× and ~1.6× fold respectively; 
P<0.05). Porosity also influenced the amount of neovascularisation within the implants, with 
no blood vessel observed in NS1 (12wks post-implantation). The lack of chronic 
inflammatory response for all materials may indicate that the elastic modulus and pore size of 
the implant scaffold could be important design considerations for influencing fibrotic 
responses to auricular and other soft tissue implants.  
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1. Introduction 
Approximately 2 in 10,000 children are born with an ear deformity (e.g. including microtia 
and anotia), whilst traumatic injuries and malignant lesions (13% of all head and neck 
melanomas) add to the need for ear replacement and reconstruction.[1-3] Off-the-shelf 
synthetic auricular implants offer a number of advantages to routine autologous costal 
cartilage reconstruction surgery currently performed including; a reduced cost and length of 
operation, and no donor site morbidity.[4] Despite synthetic scaffolds being used for over 50 
years in the auricular reconstruction surgery, they suffer from high failure rates. Medpor® 
auricular implants are the most commonly used auricular synthetic framework. Failure rates 
of between 11%-40% (depending on whether a temporoparietal fascia flap (TPFF) approach 
was used) have, however, been reported with the use of Medpor®.[5-7] There is, therefore, a 
real clinical need to develop improved biomaterials that are designed to have desirable 
biological interactions and reduced the failure rates.   
 
The host tissue integration and vascularisation following implantation of auricular constructs 
depends upon both material surface properties (e.g. chemistry, topography, micro-mechanical 
properties) and bulk properties (e.g. pore size, porosity, and mechanical properties).[8-12] The 
material surface properties determine, the type, quantity and surface confirmation of protein 
interactions, which governs subsequent cellular interactions, which in turn may affect fibrotic 
encapsulation.[13] Fibrotic encapsulation has been previously reported as a cause of implant 
extrusion and failure.[14-16] Optimising these cell-material interactions may, therefore, reduce 
fibrotic encapsulation and failure rates of auricular implants. 
Macrophages play an important part of the wound healing response when materials are 
implanted into tissues and express a large array of cytokines and chemoattractants, which 
modulate the behaviour of numerous cell types.[17-19] Macrophage behaviour can change 
depending on the adsorbed protein and the material surface properties.[20-22] Ensuring that the 
biomaterial invokes a healing inflammation response, has the mechanical properties to resist 
unintentional wear and degradation and reduce implant fibrotic encapsulation is necessary for 
the long-term survival of the implants. 
Neovascularisation is also vital for tissue regeneration and repair by supplying gases and 
nutrients for cells and tissues, and is a crucial parameter for supporting new tissue ingrowth 
in porous implants. Vascular endothelial growth factor (VEGF) is a key mediator for 
angiogenesis and granulation tissue formation in the early stage of healing,[23, 24] and can be 
expressed by fibroblasts within the peri-implant tissue. VEGF binds to its respective 
receptors, which are expressed on endothelial cells (ECs) and play important roles in 
transducing signals to induce angiogenesis in vivo through proliferation, migration and 
differentiation of ECs as well as regulates microvascular permeability.[25] Several studies 
have highlighted that an inadequate vascular supply and fibrous tissue ingrowth can be a 
cause of auricular implant failure due to the consequential flap ischemia or necrosis.[26-28] 
Indeed using vascularised grafts to completely covers the auricular Medpor® implants has 
significantly improved the short-term complication rates.[9] 
 
Previous studies have developed a porous nanocomposite scaffold (NS), named polyhedral 
oligomeric silsesquioxane nanocage into polycarbonate based urea-urethane (POSS-PCU), 
for personalised auricular reconstruction using glass moulds and 3D-printing technology to 
replicate the shape of the original human auricle (Figure 1).[29] We have also demonstrated 
that these NSs had an elastic modulus similar to native ear cartilage (5.7 MPa vs. 5.0 MPa), 
compared with Medpor® (141 MPa) (Supplementary Table S1). Matching the elastic 
modulus of the native ear may be important in preventing elastic modulus mismatch between 
the scaffold and the surrounding tissue. A material considerably stiffer than the surrounding 
tissue may cause micro-movement (when multilateral force is applied) and subsequently 
promote further fibrotic encapsulation, migration of the implant, and extrusion. Our simple 
approach is to create an “off-the-shelf” technology, whereby the scaffold matches and 
replaces the mechanical role of the ear cartilage and to improve the biological interactions of 
the scaffold with the surrounding dermal tissue. POSS-PCU has been also used successfully 
in first-in-man applications for replacement of coronary arteries, lacrimal ducts, and the 
world’s first synthetic trachea.[30-32] 
Here, we investigate the biological interactions of these NSs (compared to Medpor®) in vitro 
and in vivo, to assess the potential of the POSS-PCU NS as a substitute biomaterial implant 
for auricular cartilage replacement.  The NS interaction with serum proteins, human dermal 
fibroblasts (HDFs) and macrophages were studied. The cellular behaviour, inflammatory and 
angiogenic response of the cells on these NSs were also investigated. To this end, the NS 
with two different pore sizes were subcutaneously evaluated in vivo in a rodent model for up-
to 3 months, and compared with Medpor®. 
 
2. Results and Discussion 
2.1. In vitro evaluation of NS materials    
Biomaterials designed for auricular reconstruction need to be able to support and maintain the 
auricular shape and be able to integrate with the sub-dermal layer.  The materials properties 
(including surface chemistry, topography, mechanical properties, porosity and pore size) may 
be important in determining both 1) the initial material-cell interactions including initial 
protein adsorption, subsequent cell attachment and 2) inflammatory response, tissue ingrowth 
into the scaffold, ECM production and fibrous encapsulation. [33-38] Here we investigated if 
both these initial biological interactions and subsequent implant fibrotic encapsulation can be 
manipulated by the material physicochemical properties.  
To compare protein adsorption on NS and Medpor®, we immersed them in foetal bovine 
serum protein media for 24 hrs. An increase in the total concentration of protein adsorption 
was observed between both samples, with NS showed the greatest total percentage of protein 
adsorption (76.16% ± 7.5 μg/ml), compared to Medpor® (43.00% ± 2.6 μg/ml) within 24 hrs 
(Figure 2a). Protein absorption is both protein and substrate dependent and can be affected 
by the surface area (surface topographical features and porosity), as well as surface 
chemistry.[13, 39] Both scaffolds contain different porous structures (63.47%±1.35 total 
porosity in POSS-PCU & 50% total porosity in Medpor®) and different topographies (nano 
and microscale) (Supplementary Table S1).[29] The increased surface area of the NS caused 
by the increase in porosity and nanoscale topography will provide a larger surface area for the 
serum proteins to be adsorbed than Medpor®. NS is also less hydrophobic (53.24±0.13º) than 
Medpor® (45.67±0.23º) (Supplementary Table S1). The physiological effect of 
hydrophobicity on protein adsorption has been previously discussed, increased affinity 
between proteins and material surface may increase protein attachment but may also distort 
the original conformational of 3D protein structure, and thereby distort the cell receptor 
binding motifs and render them inactive.[40] 
 
Increased adhesion of HDFs (human dermal fibroblasts) on NS was observed in the dynamic 
and static conditions, after 24 hrs culture, compared to Medpor® (Figure 2ba,bb). The 
adhesion strength of cells in the native and continuous dynamic motion in vivo and the effects 
on wound healing and stability have been previously reported.[41] The increased cell adhesion 
on NS in both dynamic and static conditions could be explained by the increase in the 
adsorbed proteins and the increased surface area. The nanotopography of the NS may also 
have a direct effect on the adhesion strength of cells. Fibroblast filopodia number has been 
previously shown to increase on nano-featured surfaces compared to micro-featured 
surfaces.[42, 43] In addition to increased cell attachment, NS also showed an increased number 
of cells and total metabolic activity over a 14 day culture period (Figure 2ca,cb) compared to 
Medpor®, although there was no difference in the rate of proliferation, and cell metabolic 
activity/μg DNA (Figure 2cc, Supplementary Figure 2). This suggests that number of cells 
on the scaffolds was proportional to the initial cell attachment. The increase in metabolic 
activity shown in this study is contrary to our previously study where we reported no 
difference in metabolic activity of carcinogenic (3T3) cell-line between Medpor® and NS 
surfaces,[29] this may be because the primary HDFs are more sensitive to environmental 
changes than the cancerous cells used previously. 
 
The increased production of collagen hydroxyproline by HDF on NS compared to Medpor® 
(~2× fold, Figure 2da) may be due, in part, to the increased cell number (Figure 2ca). A 
higher collagen production/μg DNA (Supplementary Figure 2) was, however, observed and 
this could be due to the differences in the physicochemical properties of the scaffold 
(topography, surface chemistry etc), increased concentration of collagenic growth factors 
(e.g. TGFβ) in the media due to increased cell number, and/or increased juxtacrine 
signalling.[44, 45] The production of collagen is important for wound healing following 
invasive implantation, implant integration and tissue ingrowth, as well as to provide cell-
signalling motifs (ligands) and growth factors for guiding cell behaviour.[19, 46] Prolonged 
expression or overproduction of specific type of collagen (Coll-1α) may, however, contribute 
to increased fibrotic encapsulation.[47, 48] Interestingly the increase of collagen hydroxyproline 
on NS was consistent with the reduced production of TNF-α cytokine, compared with 
Medpor® (Figure 3da), which shown that the lowest level of this cytokine inhibit 
collagenase production.[49, 50] 
There was no difference in total VEGF production of NS (269.2 ± 17.56 pg/ml) over time of 
14 days (Figure 2db), compared with Medpor® (279.9 ± 25.58 pg/ml). A significantly higher 
VEGF production/μg DNA was, however, observed on Medpor® compared with NS 
(Supplementary Figure2). This increase could possibly be caused by the previously 
reported increase in VEGF production on stiffer surfaces.[51, 52] 
 
Initial cytokine release profiles were also measured in an effort to evaluate if the different 
surfaces of NS and Medpor® scaffolds changed the behaviour of macrophages through the 
release of IL-1β, TNF-α, and IL-10 cytokines, which are important mediators of the 
inflammatory response and wound healing.[20] The total amount of both IL-1β and IL-10 
released were similar for both NS and Medpor® at 72 hrs (Figure 3ca,ea). Macrophages cells 
attached to NS expressed lower total amounts of TNF-α (~2.4× fold) and lower TNF-α 
production/μg DNA (~2.7× fold) than on Medpor®, at 72 hrs (Figure 3da, Supplementary 
Figure 3). This may be caused by the increased expression of anti-inflammatory cytokine IL-
10 than TNF-α on NS surfaces when compared to those expressed on Medpor® (Figure 
3a,b), which inhibits the production of pro-inflammatory TNF-α cytokine, possibly via 
inhibition of NFĸB activation.[53] Both IL-1β and TNF-α cytokines are essential for wound 
healing because they induce neutrophil recruitment, maturation and encourage angiogenesis. 
Prolonged expression or overproduction of these cytokines in the inflammatory phase may, 
however, cause granulation tissue formation and subsequently increased fibrotic 
encapsulation.[50, 54, 55] Interestingly the reduced pro-inflammatory TNF-α observed by 
macrophages on NS surfaces in vitro was consistent with a reduced thickness of the fibrotic 
capsule in vivo, compared to Medpor® (Figure 3da, Figure 4cd).  
Macrophage behaviour and subsequent inflammatory response can be affected by the surface 
chemistry and surface topography of the material.[53, 56-58] The inflammatory response (lower 
expression of TNF-α and IL-1β pro-inflammatory cytokines/μg DNA on NS surfaces 
compared to Medpor®, Supplementary Figure 3ca,cb), may be due to differences in surface 
chemistry and topography between these materials (Supplementary Table S1). The scale 
and spatial arrangement of the nano-topographical features on the nanocomposite scaffold 
may be partly responsible for this reduced pro-inflammatory response. Previous studies have 
shown that nanostructure features on titanium surfaces reduced the secretion of pro-
inflammatory cytokines from macrophages.[22]  
The increased expression of pro-inflammatory cytokines IL-1β/μg DNA and TNF-α/μg DNA 
(Figure 3cb,db,eb), and reduced anti-inflammatory cytokine IL-10/μg DNA following 
endotoxin (LPS) challenge indicates that the macrophages can respond to inflammatory 
stimuli through NFĸB activation pathway, and, hence, confirming that the scaffold 
autoclaving/cleaning technique is successful in removal of the majority of endotoxins.[59] 
 
2.2 In vivo evaluation of NS implants    
In vivo studies of the NSs made of two different pore sizes ranging from 50-100µm (NS1) 
and 150-250µm (NS2), but with a constant weight ratio of porogen particles to polymer was 
assessed by subcutaneous in situ implantation in the back of a rodent model, and compared 
with Medpor® (>100 µm).  Here, the pore size of NSs was varied slightly to examine the 
effect of the changes on tissue ingrowth, angiogenesis and fibrotic response (which are not 
possible to measure in vitro). These pore sizes were chosen as an interconnective pore size of 
greater than 100 µm is required to accommodate a hierarchical vascular network within a 
scaffold,[60] with compromising the mechanical properties to native ear cartilage 
(Supplementary Table S1).  
On removal of the implants the scaffolds with the larger pore sizes (NS2 and Medpor®) were 
firmly anchored within the subcutaneous tissue compared to the NS1 (after a 12 wk 
implantation period, Figure 4aa,ac). The NS2 was, however, considerably harder to remove 
than Medpor®. Possibly because the increased surface area encouraged greater cell/tissue 
infiltration as indicated with HE staining that showed NS2 and Medpor® with 68.70±5.85 % 
and 48.1±6.4 % fibrous tissue ingrowth, respectively, compared to NS1 (11.48±2.65 %) 
(Figure 4ba,bb). This is also correlated with our earlier in vitro findings demonstrating that 
NS with a greater cellular adhesion and number by the increase in the adsorbed proteins and 
the increased surface area (surface topographical features, and porosity) (Figure 
2a,ba,bb,ca,cb). 
 
A distinct variation in both the thickness and morphology (HE staining) of the fibrous 
capsule tissue was observed between the implants (Figure 4c). In contrast to the largely 
avascular capsule with dense bundle of contractile microfilaments (elongated myofibroblasts 
and collagen fibers) seen around the smaller pore sized NS1 (Figure 4cb, white arrows), a 
network of blood vessels was observed in the capsules surrounding the other NS2 of larger 
pores and Medpor® implants (Figure 4ca,cc, black arrows).  Medpor® exhibited a thicker 
fibrosis capsule (96.43 ±16.02 μm) compared to NS2 of larger pores (Figure 4ca,cc, white 
arrows, 60.97 ± 16.07 μm). This thickening may be explained through the effect of increased 
substrate stiffness on myofibroblast formation, proliferation and collagen overproduction.[55, 
61-63] The nanocomposite scaffolds have a more similar elastic modulus to the surrounding 
native ear tissue (compared to Medpor® implant) and may therefore reduce these phenomena 
(Supplementary Table 1).[29] Softer substrates have been reported to reduce myofibroblast 
proliferation and the production of factors associated with fibrotic capsule formation (e.g. 
collagen type 1, α-smooth muscle actin (α-SMA)). [55] The poor cellular infiltration within the 
scaffolds with smaller pores (NS1) may also be contributing factor that prevents tissue 
embedded scaffold anchoring, thereby increasing interfacial micro-movement, and possibly 
contributing to inflammation and fibrotic capsule formation. A thicker capsule formation has 
been previously reported on non-porous silicone scaffolds compared to the porous Medpor® 
for auricle replacement.[64] Pores beneath a certain size, may cause a similar response to no 
pores, whereby the fibrotic membrane does not “dip” into the scaffold pores but is 
continuous. This would allow a greater fibre alignment and thereby “force” emitted on the 
material (Figure 4Cb). The thickness and type of fibrous encapsulation may be important in 
the force submitted on the material, implant migration and possibly extrusion.  Medpor® 
implants have been reported to have extrusion rates of 58% and 28%, within the rabbit and 
ovine auricular cartilage models, respectively.[65, 66]  
 
The larger pore sizes of NS2 and Medpor® implants supported the formation of new internal 
blood vessels as early as 4 wks after implantation as evidenced by vWF (vascular EC marker) 
immunostaining (Figure 5aa,ab, red arrows). No evidence of microvascularisation was, 
however, seen within the smaller pore sizes of NS1 (Figure 5ac). A scaffold with a pore size 
smaller than ~ 100 µm was previously demonstrated to have a decreased in vascularization, 
and subsequently tissue ingrowth and survival. [67] Semi-quantitative image analysis showed 
no significant differences in host tissue vascularization between the scaffolds with the larger 
pore size (Medpor® and NS2) in terms of mean microvessel size/μm2 (Figure 5ad), number 
of microvessel/mm2, and total percentage microvessel area (mm2) (Supplementary Figure 
5). Microvasculature in the NS2 were, however, clearly present within the individual pores of 
the implant that crossing between pores (Figure 5aa,ab) compared to those in Medpor® 
(Figure 5aa,ab).  Possibly advantage of neovascularization directly within the pores of the 
NSs could be the potential for a greater ability to integrate in the host environment. This is 
important because fibrovascular encasing of the implanted material is necessary for its 
anchorage in situ and for minimizing the occurrence of graft extrusion, as previously 
reported.[68-71] 
The NS2 and Medpor® materials exhibited a similar inflammatory profile (both within the 
scaffold and within the fibrotic membrane), as determined by the average number of CD68+ 
cells/μm2 (a pan specific macrophage/monocyte) (Figure 5ba,bb, red arrows). No CD68+ 
cells present within the smaller pores of NS1 which probably a reflection of the lack of 
vascularity present in this scaffold (Figure 5bc, red arrows). Number of CD68+ cells/μm2 
reduced over the 12 wks period following implantation (P<0.05), indicating no chronic 
inflammatory response for any of the implants (Figure 5bd, red arrows). Although, some 
CD68+ MNGCs (Multi-Nucleated Giant Cells) were present 12 wks post-implantation.   
Normal healing reactions without the chronic inflammatory response of these material 
implants was similar to that described in other animal models and in human using Medpor® 
implant.[65, 66, 72, 73] 
 
As opposed to the more complicated and costly tissue engineering approaches, in this study, 
we have shown that biomaterials designed with appropriate mechanical stiffness, surface 
properties and porosity, can influence biological interactions including fibrotic encapsulation. 
The lack of a chronic inflammatory response (as shown here and previously reported for 
Medpor®), may indicate that either the model is not suitable for examining soft-tissue 
implant failure (e.g. duration of experiments, site of tissue or modelling micro-movement) or 
that the high failure/extrusion rates shown could be via a different non-inflammatory 
mechanism. Here we postulate that the type and size of fibrotic membrane formation 
surrounding the implants is important in determining extrusion rates and that the 
physicochemical properties of the implant scaffold (in particular the substrate stiffness) can 
be tailored to minimize this response.  
 
3. Conclusion  
Here we demonstrated that controlling the physicochemical properties of a biomaterial 
influences soft-tissue implant interactions (including fibrotic encapsulation) and can therefore 
lead to the design-led development of auricular implants that reduce failure rates. The in vitro 
and in vivo preclinical models used in this study provided, respectively, a setting to evaluate 
the clinical suitability and the subcutaneous behaviour of NSs, which had an elastic modulus 
closer to native ear cartilage (compared with the currently used auricular Medpor® implant).  
We demonstrated that NSs showed greater protein adsorption, and subsequently increased 
HDF adhesion (at both static and dynamic conditions), proliferation, and collagen production 
in vitro, compared to Medpor®. This was correlated to the in vivo findings, where the larger 
pore sized NS2 (150-250μm) demonstrate greater integration with the surrounding tissue, and 
a higher percentage of tissue ingrowth compared with both Medpor® and NS1 of smaller 
pores (50-100μm). At 12 wks post-implantation, significantly less fibrotic encapsulation was 
observed with elastic NS2 of large pores when compared with elastic NS1 of smaller pores 
and rigid Medpor® implants. The NS2 scaffold with larger pores of 150-250μm presented a 
promising alternative biomaterial for auricular reconstruction. The next stage will be focused 
on preclinical studies to fully establish the performance of 3D auricular scaffold made from 
this NS2 under GLP standards before embarking on clinical trials.  
 
4. Experimental Section  
Synthesis of Nanocomposite Polymer: POSS-PCU nanocomposite polymer was synthesised 
as described previously.[74] Briefly, polycarbonate polyol, 2000mwt and trans-
cyclohexanechloroydrinisobutyl-Silsesquioxane (Hybrid Plastics Inc) were placed in a 500ml 
reaction flask equipped with mechanical stirrer and nitrogen inlet. The mixture was heated in 
order to dissolve the POSS cage into the polyol and then cooled to 70°C. Flake 4,4’-
Methylenebis(phenyl isocyanate) (MDI) were added to the polyol blend and then reacted, 
under nitrogen, at 75°C - 85°C for 90 minutes to form a pre-polymer. Dimethylacetamide 
(DMAC) was added slowly to the pre-polymer to form a solution; the solution was cooled to 
40°C. Chain extension of the pre-polymer was carried out by the drop wise addition of a 
mixture of Ethylenediamine and Diethylamine in DMAC to form a solution of POSS 
modified Polycarbonate urea-urethane in DMAC. All the chemicals used in this study were 
received from Sigma-Aldrich Limited (Gillingham, UK). 
 
Fabrication of Nanocomposite Scaffolds: NSs were synthesized and produced through 
optimized solvent evaporation and porogen leaching fabrication methods, as previously 
described.[29] The weight ratio of NaCl particles to POSS-PCU was controlled to 3:7 as with 
the previous studies. NSs with an average pore size of 150 μm, and a thickness of 700-800 
μm, were cut into 16 mm diameter discs for use in 24 well plates, and used for in vitro cell 
culture experiments (n=4).  Tissue culture plastic (TCP) used as control sample.  The same 
NS discs (16mm in diameter), but with different thickness (~1.5 mm) and different pore sizes 
ranging from (50-100 μm) and (150-250 μm) were used for in vivo implantation (n=4 NS 
each time point). The pore size and morphology of these NSs was confirmed using scanning 
electron microscopy (SEM) (Supplementary Figure 4). Micro thin Medpor® medical grade 
high-density porous polyethylene (HDPE) (Porex Surgical, Newnan, GA USA) (1.5 mm 
thickness sheets) with a manufacturer-specified pore size of larger than 100 μm and a pore 
volume of 50% were cut into circle-shaped disks (16 mm in diameter), and used for 
comparison (n=4 scaffolds each time point). Details of the physicochemical characterization 
of these NSs and Medpor® used in in vitro and in vivo were presented in Supplementary 
Information and methodology section (Supplementary Table S1).  
 
Protein Adsorption Studies:  Protein adsorptions of scaffold surfaces were assessed using 
BCA kit (Bicinchoninic acid assay; PierceTM thermo scientific, Rockford, IL USA), 
following the manufacturer’s protocol. Polymer samples were prewetted in 70% ethanol for 
30 min, and rinsed (x3) with PBS overnight under gentle shaking (25 rmp). Samples were 
then immersed in PBS supplemented with 20% fetal bovine serum proteins (FBS) for 
incubation periods of 24 hrs. After which samples washed (x4) with PBS, immersed for 1 hr 
in 1% sodium dodecyl sulphate in deionized H2O to retrieve adherent proteins in shaker, and 
incubated at 37 ºC for 30 min in working reagents. The absorbance eluted stain was measured 
using a colorimetric microplate reader (Anthos 2020) at 562 nm. Standard curves obtained 
from a series of dilutions of known standard bovine serum albumin (BSA) concentrations. 
 
In vitro Biological Interactions:  The interactions of HDFs with the NSs and Medpor® were 
assessed through cellular adhesion, proliferation, ECM collagen production and angiogenic 
response in this study. In order to determine the strength of cell adhesion on materials in a 
dynamic environment, total DNA using fluorescent Hoechst 33258 stain (Benzamide 33258, 
Sigma, UK), and Alamar Blue® (AB; Serotec Ltd, Kidlington, Oxford, UK) assays were 
performed at 24 hrs after initial cell seeding to determine the number of cells adhered on 
tested samples. Dynamic condition was performed using an orbital shaker (50 rpm) (Grant 
Bio PSU-10i; Wolf Laboratories Limited, York, UK), and optimised by a preliminary study 
examining the effects of different speeds (static, 50 rpm, 140 rpm, and 200 rpm) on adhesion 
of HDF cells seeded on TCP. Total DNA and AB assays were also used to determine the 
HDF proliferation and viability of the materials, respectively, on day 1, 3, 7, and 14 of 
culture. Total amount of extracellular secreted collagen (soluble and insolubilised) by HDF in 
the samples was measured on day 3, 7, and 14 using the hydroxyproline assay kit 
(QuickZyme Biosciences, Leiden, The Netherlands). The angiogenic response of HDF on 
materials was also determined by release of VEGF quantification using a sandwich enzyme 
linked immunosorbent (ELISA; Quantikine, R&D System, Abingdon, UK) assay on day 3, 7, 
and 14 of culture. Macrophage responses to NSs and Medpor® were investigated by 
transformed U937 macrophage proliferation, cell morphology, and cytokines release 
assessments. Total DNA was performed on 24, and 72 hrs of culture to determine 
macrophage proliferation on materials (Supplementary Figure3). Following day 3, 
macrophage morphology and adhesion on materials was determined using SEM 
(Supplementary Figure3). Cytokines release including, IL-1β, TNF-a, and IL-10 
quantification in response to material surfaces were assessed at 24, and 72 hrs using a 
sandwich ELISA assay (Quantikine, R&D System, Abingdon, UK). Samples with 
lipopolysaccharides (LPS) were used as positive controls. See Supplementary Information 
and the Methodology section for each individual test. 
 
Rodent Animal Model and In vivo Evaluation:  All procedures were conducted in accordance 
with protocols approved by the Royal Free Hospital (London, UK) on Animal Care. The 
experiments were conducted of eighteen adult male Sprague–Dawley rats (Charles River 
UK), weighing 250–400 g, were used for animal study. Each animal underwent implantation 
with two different material scaffolds from each three groups (NS1 (50-100μm), NS2 (150-
250μm), and Medpor® (>100 μm)) in the dorsal subcutis of rats. Under aseptic technique and 
after shaving the subcutaneous pockets were made on each side of the midline into which 
each implant was placed through single incision. Each scaffold samples (n=4 per time point) 
were implanted subcutaneously at 1 cm from the site of incision. After 4, 8, and 12 wks, the 
implanted materials plus surrounding tissue were dissected from the subcutaneous pocket. 
Extracted samples (peri-implant tissue included) were labelled (orientation noted) and fixed 
in 10% (v/v) NBF before paraffin embedded for standard histology analysis to assess tissue 
ingrowth and fibrous capsule thickness, and IHC to assess micro-neovascularisation and the 
host inflammatory responses using von Wilibrand Factor (vWFs) and CD68 staining, 
respectively (see Supplementary Information and the Methodology section). Thereafter, the 
animals were sacrificed by cervical dislocation. 
 
Statistic: All quantitative data are presented as means ± standard deviation (SD). The 
differences between samples during repeated-measures testing was calculated by one-way or 
two-way analysis of variance (ANOVA) using Tukey's post hoc test, or two-tailed unpaired 
Student t-tests (for parametric data), with significance accepted at the 5% level using 
GraphPad Prism 6 Software. 
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Figure Legends  
Figure 1. Design and construction of a porous auricular framework and in vitro and in vivo 
testing of its properties in a 3-D circle-shaped disc.  a, Standard triangulate language (STL) files 
format taken from a CT scan data of the external part of a human ear model is sliced into thinner 
horizontal layers of powder, and solidified by a binder using, b, an additive layer manufacturing 
(ALM) software. b, Positive 3-D printing auricle mould using ALM based on powder bed and inkjet 
3D printing is used, to design a, c, negative ear glass-mould to construct a, d, auricular POSS-PCU 
nanocomposite scaffold through a solvent evaporation/porogen leaching fabrication technique. da, 
SEM cross-sectional of the porous nanocomposite scaffold, and db, a schematic diagram of the 
chemical structure of poly-oligomeric silsesquioxane (POSS) nanocages.  
 
Figure 2. In vitro biological evaluation of HDFs of the NSs compared to Medpor®. a, A 
significantly lower level of protein adsorption was observed on Medpor® compared with NS at 6 and 
24 hrs. ba, and bb, A significantly higher percentage of metabolic activity and number of HDFs 
attached on NS compared to Medpor® after 24 hrs at dynamic and static culture (relative to TCP %). 
ca, higher HDFs number and cb, higher metabolic activity were presented on NS compared with 
Medpor® at day 7 and 14. cc, No significant differences in cell proliferation rate were observed 
between the scaffolds after 14 days of culture (% of total DNA relate to day 1). da, A significantly 
higher amount of collagen production was found on NS over 14 days culture. db, no significant 
difference in level of VEGF production was observed between both scaffolds over 14 days. *P < 0.05, 
errors bar=SD, (n=4, scaffolds in each group at each time-point). 
 
Figure 3. In vitro inflammatory responses of macrophages of the NSs compared to Medpor®. a, 
POSS-PCU surfaces expressed a significant increase in IL-10 concentration by U937 cells after 72 hrs 
into the supernatants, and showed a highest level of IL-1β and IL-10 respectively, and a lowest level 
of TNF-α cytokines production on both 24 and 72 hrs culture. b, Medpor® surfaces also expressed a 
significant reduction in IL-1β, and a significant increase in IL-10 concentrations after 72 hrs culture 
into the supernatants, and presented a highest level of IL-1β cytokines production compared to the 
other two cytokines on both 24 and 72 hrs. ca, da, and ea, No significant differences in IL-1β and IL-
10 production were observed between the two scaffolds during 72 hrs period. However, a significant 
increase in TNF-α was found on Medpor®. cb, db, and eb, LPS treatment resulted in a significant 
increased in pro-inflammatory IL-1β and TNF-α cytokines production/μg DNA, but not anti-
inflammatory IL-10 cytokine on both scaffold surfaces at 72 hrs. *P < 0.05, errors bar=SD, (n=4, 
scaffolds in each group at each time-point). Scale bar 20 μm. 
 
Figure 4. In vivo tissue ingrowth and fibrotic encapsulation evaluation of the NSs implants in 
rats compared to Medpor®. a, Observation on retrieval of implanted materials at 12 wks 
subcutaneous post-implantation in the rat model. All implanted materials preserved their pre-
implanted round shapes. aa, POSS-PCU (150-250μm; NS2) and, ac, Medpor® were firmly anchored 
within the subcutaneous tissue (white arrows), but ab, POSS-PCU (50-100μm; NS1) were loosely 
attached with the surrounding soft tissue (white arrow). b, Fibrous tissue ingrowth within all the 
implanted materials demonstrated by, ba, a H&E evaluation and bb, a percentage volume fraction of 
fibrous tissue representing the proportion of total scaffold volume (area between white dash lines) 
occupied by fibrous tissue at 4, 8, and 12 wks. Scale bars represent 500 μm. *P < 0.05, errors bar=SD. 
c, Fibrous encapsulation of all the scaffolds at 12 wks post-implantation presented by, ca, a H&E 
evaluation and, cb, a semi-quantitative histological analysis of fibrous capsule thickness (white 
arrows) around the implants. The tissue-implant interface where the capsule not attached to POSS-
PCU of smaller pores (blue asterisk). Some blood vessels surrounded the implants (black arrows). 
Scale bars represent 100 μm. (n=4 scaffolds in each group at each time point). 
 
Figure 5. In vivo neovascularisation and host macrophage responses evaluation of the NSs 
implants compared to Medpor®. a, Endothelial staining with vWFs IHC (red arrows) revealed 
vessel lumens area of 12 wks observed within, aa, POSS-PCU (150-250μm; NS2), ab, Medpor®, but 
not on, ac, POSS-PCU (50-100μm; NS1) implants. ad, A measured mean microvessel size/μm2 in 
large pore sizes of POSS-PCU and Medpor® implants, representing the size of blood vessels within 
grown tissue per scaffold, as quantified at 4, 8, and 12 wks, with no observable significant differences 
between the groups. b, Pan-macropahge/monocyte staining with CD68 IHC (red arrows) of 12 wks 
observed in host tissue across and within, ba, POSS-PCU (150-250μm; NS2) and, bb,  Medpor®, and, 
bc, surrounding POSS-PCU (50-100 μm; NS1) implants (but no sign of CD68 positive staining within 
the implants). bd, Quantitative IHC represented a significantly reduced average number of positive 
macrophage cells across and within the POSS-PCU of smaller pores compared with other scaffolds 
per field of view area, at all time points. *P < 0.05, errors bar=SD, (n=4, scaffolds in each group at 
each time-point). Scale bars 50 μm. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
26 
 
Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
Figure 3.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
Figure 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
Figure 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
Supplementary Information  
 
 
Supplementary Experimental Section  
 
Physicochemical characterisation of materials. The surface chemistry, topography, and 
mechanical properties of the POSS-PCU nanocomposite scaffold (NS) and Medpor® have 
been previously characterised and the protocols were published in detail.[1] The changes in 
the pore size of NSs changed the mechanical and total porosity, but not the chemistry. A table 
summary of the physicochemical properties of these materials was presented 
(Supplementary Table 1).  
 
In vitro biological interactions  
Fibroblast culture. Human dermal fibroblast (HDF) cell derived from the dermis of normal 
human neonatal foreskin or adult skin (ECACC, UK, Number 06090715), were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% foetal bovine serum 
(FBS) and 1% antibiotic (50 μg/mL streptomycin, 50 U/mL penicillin) solutions (all from 
Invitrogen, UK) and incubated at 37 ◦C.  The 16 mm polymer discs (n=4) were autoclaved, 
washed in sterile phosphate-buffered saline (PBS) and pre-incubated in 1 ml of supplemented 
Table S1. Physicochemical properties of POSS-PCU nanocomposite scaffolds (NSs) and Medpor® used in in 
vitro and in vivo studies. *Data obtained from previously published results. [1]  
 
Samples Average 
Pore size 
(µm) 
Total 
porosity 
(%)+ 
Youngs 
modulus 
(MPa) 
Contact angel 
(captive 
bubble) (θ) 
Mean root square 
roughness (Rq) (nm) 
POSS-PCU* ~150  63.47±1.35 5.73±0.17  53.24±0.13º 82.2±11.8 
POSS-PCU 
(NS1) 
50-100 57.04±1.15 5.84±0.23  53.24±0.13º* 82.2±11.8* 
POSS-PCU 
(NS2) 
150-250 69.70±1.42 4.09±0.29  53.24±0.13º* 82.2±11.8* 
Medpor®*  >100 50 140.9±0.04  45.67±0.23º 119.0±13.8 
Rq indicates mean root square roughness; Values are mean±SD, (n=4).  
+Weight ratio of porogen particles to POSS-PCU was 3:7 for all NS samples. 
* Youngs modulus of human auricular cartilage was 5.02±0.04 (MPa), respectively.   
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culture media for 24 h overnight. Each polymer disc was seeded with cells at a density of 4 x 
104 cells/cm2 in 1 ml of cell culture medium. Media were replaced every two days.  
 
Macrophage culture. The human promonocytic cell line U937, isolated from a histiocytic 
lymphoma (ECACC, UK, Number 85011440), were cultured in RPMI-1640 supplemented 
with 10% foetal bovine serum (FBS), 5% L-glutamin (2mM) and 1% antibiotic (50 μg/mL 
streptomycin, 50 U/mL penicillin) solutions (all from Sigma, UK) and incubated at 37 °C 
under a humidified atmosphere of 5% CO2. The non-adherent undifferentiated U937 washed 
(x3) every 3-4 days in Hank’s balance solution. The 16 mm polymer discs (n=4) were 
autoclaved and washed in sterile PBS, and pre-incubated in 1 ml of supplemented culture 
media for 24 hrs overnight. Each polymer disc in 24 well plate was seeded with U937 cells at 
a density of 1 x 105 cells/cm2 in 1 ml of cell culture medium supplemented with 0.5 nM 
phorbol-12-myristate 13-acetate (PMA) (Sigma, UK). Under these conditions, U937 
monocytes will adhere to surfaces and differentiate into macrophage-like cells. After 24 hrs 
the wells were aspirated to remove any unattached, and non-differentiated monocytes, and 
replaced with fresh medium. Lipopolysaccharide (LPS), a gram-negative bacterium, (Sigma, 
UK) stimulated transformed macrophages on the polymer surfaces at a concentration of 1 
µg/ml as positive control. 
DNA content quantification via Total DNA Hoechst staining. Briefly, cells were lysed 
(x3) using freeze-thaw cycles following the removal of cell culture supernatants stored froze. 
Lysed cells were stored in a freezer at -80°C and thawed to room temperature. The lysate 
were incubated with molecular biology grade water (Sigma, UK) for 1 hr in each cycle and 
Hoechst stain was added at a final concentration of 2μg/ml. The fluorescence of Hoechst dye 
was measured at 360 nm excitation wavelength and 460 nm emission wavelength using a 
fluorescence microplate reader (Fluoroskan Ascent FL, Thermo Labsystems, UK). Total 
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DNA and cell number standard curves were obtained from serial dilutions of known DNA 
concentrations (positive control) (calf thymus, Sigma, UK) and different cell densities, 
respectively.  
Cell metabolism via Alamar Blue® (AB) assay. Briefly, 10% (v/v) of AB (100 µl/mL 
solution of AB in DMEM) was added to the culture media of the cell-seeded polymer discs 4 
hrs prior to the end of cell culture. Aliquots (100 µl) were placed in a 96 well plate, and the 
absorbance read on a fluorescence plate reader (Fluroskan Ascent FL reader, Thermo 
Labsystems, Basingstoke, UK) at 530 nm excitation wavelength and 620 nm emission 
wavelength.  
Total Extracellular Collagen production via Hydroxyproline assay. The measurement of 
hydroxyproline residues needed for stabilization of the collagen triple helix, known as 
procollagen, was used as a relevant marker for total amount of secreted collagen from cell 
cultures. Hydroxyproline is a non-proteinogenic amino acid, which results from the 
hydrolysis of all types of collagen present in the sample, without discriminating between 
collagen, insoluble, cross-linked collagen, and soluble collagen. Briefly, the supernatant (250 
µl) of each sample was acid hydrolysed in 12M hydroxyl chloride (HCl) at 90 °C for 20 
hours, diluted at least twofold using 4M HCl, centrifuged each for 10 min at 13,000 (xg), and 
analysed for hydroxyproline using a colorimetric kit, according to the established protocol. 
The diluent sample (35 µl) was dispensed into 96-well plates, added with assay buffer (75 
µl), and incubated at room temperature for 20 min. After that 75 µl of detection reagents was 
placed in each well for 60 min at 60 °C. The absorbance eluted stain was measured at 570 nm 
in a microplate reader (Anthos 2020 microplate reader, Biochrome Ltd, UK) and the amount 
of soluble and insoluble collagen estimated. Results were calculated by interpretation from a 
standard curve obtained from serial dilutions of hydrolysis rat-tail collagen standard (positive 
control), following manufacturer’s instructions. 
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Vascular endothelial growth factor (VEGF) production. The concentration of VEGF was 
quantified using a sandwich enzyme linked immunosorbent assay (ELISA) kit following the 
manufacturer’s protocol. Briefly, cell culture supernatants seeded on each polymer surface 
were centrifuged at 200g for 10 min and aliquoted and stored at –20 oC. A monoclonal 
antibody specific for VEGF had been pre-coated onto the ELISA 96 well micro-plate. The 
supernatants from each sample (duplicated of 200 µl) were pipetted into these wells and 
incubated for 2 hrs at room temperature, any VEGF present were bound to the immobilised 
anti-VEGF antibody. After aspirating and washing an enzyme linked anti-VEGF polyclonal 
antibody is added to the wells (200 μl for 2 hrs at room temperature), followed (after 
washing) by the addition of the substrate solution (200 μl) and incubated for 20 min at room 
temperature. The colour develops proportionally to the amount of VEGF present. The colour 
development was stopped (50 μl of stop solution R&D) and the colour intensity measured 
with a colorimetric plate reader (Anthos 2020 microplate reader, Biochrome Ltd, UK) at 450 
nm with a wavelength correction of 540 nm within 10 min of addition of stop solution. 
Results were calculated by interpolation from a standard curve obtained from serial dilutions 
of known human recombinant VEGF (positive control), according to manufacturer’s 
instructions. This assay detects human VEGF164 (the predominant isoform) with a sensitivity 
of 5 pg/mL in the range of 15–1000 pg/mL.  
Cytokine release. The concentration of released cytokines including, interleukin-1 (IL-1β/ 
IL-1F2), tumour necrosis factor (TNFa/ TNFSF1A), and IL-10 were determined using 
specific ELISA kits following the manufacturer’s protocols. Briefly, cell culture supernatants 
seeded on each polymer surface were centrifuged at 200g for 10 min and aliquoted and stored 
at –20 oC. A monoclonal antibody specific for each cytokines had been pre-coated onto the 
ELISA 96 well micro-plate. The supernatants from each sample (duplicated of 200 µl) were 
pipetted into these wells and incubated for 2 hrs at room temperature, any related specific 
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cytokines present bound to the immobilised anti-related cytokine antibody. After aspirating 
and washing an enzyme linked anti-related cytokine polyclonal antibody is added to the wells 
(200 μl for 1 hr at room temperature), followed (after washing) by the addition of the 
substrate solution (200 μl) and incubated for 20 min at room temperature. The colour 
develops proportionally to the amount of related cytokine present. The colour development 
was stopped (50 μl of stop solution R&D) and the colour intensity measured with a 
colorimetric plate reader (Anthos 2020 microplate reader, Biochrome Ltd, UK) at 450 nm 
with a wavelength correction of 540 nm within 30 min of addition of stop solution. Results 
were calculated by interpolation from a standard curve obtained from serial dilutions of each 
known human cytokines (positive control), according to manufacturer’s instructions.  
 
In vivo evaluation   
Histology assessments. Following fixation, the length of each post-implantation scaffold was 
measured in millimeters and sliced horizontally (from top) into ∼4 sections of roughly equal 
thickness in preparation for paraffin wax embedded. Following routine H&E staining on 5-
μm sections, the stained samples were observed by using the light microscope (Leitz, 
Wetzlar, Germany) fixed with a multispectral imaging system (CRi-Nuance™ FX, USA), 
and the percentage volume fraction of fibrotic tissue (VF) ingrowth within each scaffold for 
each implantation period was estimate by using an ImageJ software, version 1.47 (National 
Institute of Health, USA) technique of area counting covered with ingrown fibrotic tissue. 
Connective tissues enmeshed with spindle-shaped fibroblasts were considered as an ingrown 
fibrous tissue; while round-shaped cells and rare spindle-shaped fibroblasts in the most inner 
area were considered as non-ingrown fibrovascular tissues as previously described.[2] All 
estimations were analyzed at a final magnification of 4× and 24 fields of view for each 
scaffold (n=4). The area of tissue ingrowth was measured at three different areas evenly 
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distributed in each of the 2 middle-area of scaffold sections (~ depth 6mm from the external 
surface of the implant edge to central end point of ingrowth) for each scaffold. Briefly, area 
test points were randomly superimposed onto the surface of each imaged scaffold section, 
and the area of test points overlying tissue ingrowth were counted for each evenly random 
selected field of view. The sum of all area points hitting the tissue ingrowth was divided by 
the sum of all points hitting the scaffold area over all fields analyzed, generating a percentage 
volume fraction of the scaffold occupied by ingrown fibrotic tissue (%VF).  
The thickness of the fibrous capsule was measured at a final magnification of 10× and six 
different points (from the implant margin to the end point of fibrous encapsulation) of each 
randomly and uniformly selected imaged scaffold sections for each scaffold (n=4). The 
reported thickness values were indicated using semi-quantitative image analysis using the 
ImageJ software.  
Immunohistochemistry (IHC) assessments. Details of the immunohistochemistry staining 
protocols for von Wilibrand Factor (vWF) and CD68, respectively, for characterising 
vascular EC and pan-macrophage/monocyte cell markers were presented (Supplementary 
Table 2).  
Table S2. Pretreatment and dilutions of antibodies for immunohistochemistry labelling of endothelial cells 
(ECs), and macrophages markers using vWF, and CD-68 staining, respectively.   
Antigen Retrieval Blocking 
Solution 
Primary Antibody Peroxidase 
substrate  
Secondary Antibody 
Proteinase K, PH 
7.5, 3-6 min (Dako 
S3020) 
2.5% normal 
horse serum- 30 
min (readymade 
Vector MP-
7401) 
Polyclonal rabbit 
anti-human von 
Willebrand factor- 2h 
(vWF A0082, Dako 
Ab & Dako Ab 
diluent S0809) 
1:50 diluted 
Diaminobenzidine 
(DAB)- (brown) 
(Vector SK-4105) 
ImmPRESS™ anti-Rabit 
immunoglobulin- 30 min 
(readymade Vector MP-
7401) 
 
Proteinase K, PH 
7.5, 3-6 min (Dako 
S3020) 
2.5% normal 
horse serum- 30 
min (readymade 
Vector MP-
7402)  
Monoclonal mouse 
anti-human 
CD68, clone 
MAC387- 2h (anti-
L1 Thermo 
Scientific™, PIMA 
133969) 
1:100 diluted  
Diaminobenzidine 
(DAB)- (brown) 
(Vector SK-4105) 
ImmPRESS™ anti-Mouse 
immunoglobulin- 30 min 
(readymade Vector MP-
7402) 
 
* 3% hydrogen peroxide diluted in Methanol- 30 min (Sigma Aldrich) used to inhibit endogenous peroxidase activity. 
Hoechst 33258 was used as the nuclear stain. As negative controls, immunohistological stained in the absence of the 
primary antibody. 
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Blood vessels formation was identified via immunolocalization with the ECs marker, vWF. 
The percentage volume fraction of the stained microvasculature within each host tissue of 
implanted scaffolds (total percentage microvessel area (mm2)) was estimated by using the 
previously described technique of area counting overlying small blood vessels for each 
evenly random selected field of view. All estimations were analyzed at a final magnification 
of 40× and 32 fields of view for each scaffold (n=4). The volume fraction was considered the 
main tissue within scaffold related parameter characterizing the extent of neovascularization 
(reflecting both the number and size of new small blood vessels). 
 
Host macrophage inflammatory response was identified via immunolocalization with the pan-
macrophage/monocyte cell marker, CD-68. Immunolabeled sections (5-μm) were used to 
obtain the average cell counting of CD68 pan-macrophage/ monocyte positive cells within 
the implants. The stained samples were observed by using the light microscope (Leitz, 
Wetzlar, Germany) fixed with a multispectral imaging system (CRi-Nuance™ FX, USA) at 
magnification 40×. An unbiased sampling frame was applied under Image J software control 
to each uniformly and randomly selected image (field of view). Average cell counting data 
was obtained on approximately 32 fields of view (25 x 104 µm2) per scaffold (n=4) by using 
a uniform random sampling approach. 
 
 
Supplementary Figure Legends  
Figure S2. In vitro biological evaluation of HDFs of NS compared to Medpor®. a, A significantly 
higher collagen production per cell was observed on NS than Medpor® over 3 days , followed by 
non-significant increase after day 7. b, A significantly higher VEGF release per cell was obtained on 
Medpor® than NS at 14 days.   
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Figure S3. In vitro inflammatory responses of macrophages of the NSs compared to Medpor®. 
aa, No significant difference in total U937 cell number and ab, in rate of cell proliferation (% of total 
DNA relate to day 1) was observed on both NS and Medpor® scaffolds over 72 hrs. ba, and bb, 
Scanning electron microscopy (SEM) micrograph images of transformed adhered U937 macrophages 
with rounded cell morphology (red arrow) after 3 days culture on NS and Medpor®. ca, and cc, No 
significant differences in IL-1β/μg DNA, and IL-10/μg DNA cytokines production was observed on 
both NS and Medpor® after 72 hrs, apart from cc, TNF-α/μg DNA that presented a significantly lower 
production on NS than Medpor®.  
 
Figure S4. In vivo nanocomposite scaffold microstructure. SEM images of the cross-sectional of 
POSS-PCU (50-100μm; NS1) and POSS-PCU (150-250μm; NS2). The pore size is correlates closely 
with porogen particular size as expected.  
 
Figure S5. In vivo neovascularisation and host macrophage responses evaluation of the NSs 
implants compared to Medpor®. a, Number of microvessel/mm2, and b, total percentage 
microvessel area (mm2) in large pore sizes of NS and Medpor®, representing the number, and volume 
of occupied blood vessels within grown tissue per scaffold, as quantified at 4, 8, and 12 wks, with no 
observable significant differences between the groups.  
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